WO2024052863 - AQUEOUS PHARMACEUTICAL COMPOSITIONS COMPRISING BENZYL ATROPINE AND USES THEREOF
National phase entry:
Publication Number
WO/2024/052863
Publication Date
14.03.2024
International Application No.
PCT/IB2023/058890
International Filing Date
07.09.2023
Title **
[English]
AQUEOUS PHARMACEUTICAL COMPOSITIONS COMPRISING BENZYL ATROPINE AND USES THEREOF
[French]
COMPOSITIONS PHARMACEUTIQUES AQUEUSES COMPRENANT DE LA BENZYL ATROPINE ET LEURS UTILISATIONS
Applicants **
ALCON INC.
Inventors
KETELSON, Howard Allen
RANGARAJAN, Rekha
Priority Data
63/375,236
11.09.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2262 | |
| EPO | Filing, Examination, Granting | 10589 | |
| Japan | Filing, Examination, Granting | 2279 | |
| South Korea | Filing, Examination, Granting | 2323 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
22,193
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present disclosure is directed, in part, to aqueous pharmaceutical solutions comprising benzyl atropine or a pharmaceutically acceptable salt or prodrug thereof, at least one buffer, at least one tonicity agent, and at least one solubilizing agent, processes of preparing an aqueous solution comprising benzyl atropine, the products of such processes, and methods of preventing myopia, treating myopia, reducing myopia progression, or preventing myopia progression in a subject in need thereof, by administering to the eye of the subject a therapeutically effective amount of such an aqueous pharmaceutical solution.[French]
La présente invention concerne, en partie, des solutions pharmaceutiques aqueuses comprenant de la benzyl atropine ou un sel pharmaceutiquement acceptable ou un promédicament associé, au moins un tampon, au moins un agent de tonicité, et au moins un agent de solubilisation, des procédés de préparation d'une solution aqueuse comprenant de la benzyl atropine, les produits de tels procédés, et des méthodes de prévention de la myopie, de traitement de la myopie, de réduction de la progression de la myopie, ou de prévention de la progression de la myopie chez un sujet en ayant besoin, par administration à l'œil du sujet d'une quantité thérapeutiquement efficace d'une telle solution pharmaceutique aqueuse.compositions pharmaceutiques aqueuses comprenant de la benzyl atropine et leurs utilisations